Synonyms: (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H.8,4-(metheno)pyrazolo[4,3.h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile; PF-06463922; PF-6463922
Molecular Formula: C21H19FN6O2
Molecular Weight: 406.41
Linear Structural Formula: C21H19FN6O2
MDL Number: MFCD28144520
Purity: >=98% (HPLC)
Storage: room temp
Biochem Physiol Actions: Lorlatinib (PF-06463922) is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against most known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. It is in clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Legal Information: Sold for research purposes under agreement from Pfizer Inc.